$TDOC

Teladoc Health (TDOC) introduced SoloVitals and SoloScribe, AI tools for virtual visits. The stock is down 11.46% in 30 days and 39.63% in 90 days, with a 1-year return decline of 38.83%. Analysts suggest it may be 63% undervalued, citing a fair value of $15.00. The company has $750M in cash and generates $130M-$170M in annual free cash flow, but faces risks from competitors and pricing pressures.

Teladoc Health announced new AI features for its virtual care platform, including remote patient monitoring and AI-driven clinical note transcription. SoloVitals, for contactless vital sign tracking, is in private preview, while SoloScribe is available now. The company aims to streamline care teams' workflows. Teladoc reported a net loss of $200.3 million in 2025 and lowered its 2026 revenue outlook to $2.36B-$2.45B, citing challenges in its mental health division, BetterHelp.

Teladoc Health (TDOC) launched AI features SoloVitals and SoloScribe for its Solo platform. SoloScribe is available now, while SoloVitals is in private preview with a general release expected in December 2026. The features aim to enhance hospital penetration and AI integration.

Teladoc (TDOC) shares fell 2.3% to $5.95 amid leadership transition concerns. The company's CLO resigned, raising governance questions. The stock has declined since Q2 revenue missed expectations and guidance was cut. Analysts have lowered price targets, and institutional selling has increased. The broader market's decline added pressure. TDOC trades near its 52-week low of $4.40.

Teladoc Health, Inc. (TDOC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, Mr. Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc. (the "Company"),

DIVITA CHARLES III (CHIEF EXECUTIVE OFFICER) sold 17,805 shares of Teladoc Health, Inc. (TDOC) at $6.10 ($0.11M total) on 2026-09-11.

Teladoc Health (TDOC) and Recursion Pharmaceuticals (RXRX) face significant challenges. Teladoc's revenue declined 4% YoY to $606.9M, with BetterHelp's revenue and users dropping 12% and 11% YoY, respectively. Recursion, an AI-driven biotech, lacks approved products and has seen its stock fall 21% over the past year. Both companies show dim prospects, according to the analysis.

Teladoc Health's (TDOC) Integrated Care segment is driving profitability, generating $394.3M in Q2 revenue and $65.2M in adjusted EBITDA. The segment's focus on chronic care and enterprise contracts positions it for growth, while Teladoc One, launching in 2027, could further boost earnings. TDOC shares have gained 18.5% over six months, trading at a forward P/S ratio of 0.47X.

Teladoc Health granted new CFO Michael Grasher 239,616 restricted stock units and performance stock units, with vesting tied to service and financial targets. The performance stock units are linked to 2026 EBITDA and 2026-2028 revenue growth.

DIVITA CHARLES III (CHIEF EXECUTIVE OFFICER) sold 18,327 shares of Teladoc Health, Inc. (TDOC) at $6.30 ($0.12M total) on 2026-09-02.